This clinical trial focuses on studying a new medication called PF-07275315 in people who have moderate-to-severe asthma. Asthma is a lung condition that makes breathing difficult and causes symptoms like wheezing, coughing, and shortness of breath. The study aims to determine how well this new medication works and how safe it is for patients whose asthma is not well controlled with their current treatments.

The study medication PF-07275315 will be given as a subcutaneous injection, which means it is injected under the skin. Some participants will receive the actual medication, while others will receive a placebo. The study will last for 12 weeks, during which participants will receive different doses of the medication or placebo.

During the study, doctors will measure how well participants’ lungs are working by checking their forced expiratory volume, which shows how much air a person can breathe out in one second. They will also monitor participants’ overall health and any changes in their asthma symptoms. The medication is specifically being tested in people who have higher levels of certain white blood cells called eosinophils in their blood.